desktop bg

    ASCO GU 2026

    Presentations Supported by Bayer

    February 26-28, 2026

    Agenda of oral and poster presentations at the 2026 Genitourinary (GU) Symposium of the American Society of Clinical Oncology (ASCO).


    Please see below to download a PDF for each presentation and view a video (where applicable). Access for each publication will be available after the congress presentation.

    Please select a compound to navigate to all related publications.

    DAROLUTAMIDE

    desktop listing bg

    Efficacy and safety of darolutamide and ADT in patient subgroups by baseline comorbidities and concomitant medications: ARANOTE
    post hoc
    analyses

    Date/Time:
    February 26, 2026 | 11:30 AM – 12:45 PM; 5:45 PM – 6:45 PM (PST)

    Session:
    Poster Session A: Prostate Cancer

    Type:
    Poster

    Presenting Author:
    Fred Saad

    Poster Board Number:
    F7

    desktop listing bg

    Analysis of quality-adjusted time without symptoms or toxicity (Q-TWiST) in patients with metastatic hormone-sensitive prostate cancer: From the ARASENS trial

    Date/Time:
    February 26, 2026 | 11:30 AM – 12:45 PM; 5:45 PM – 6:45 PM (PST)

    Session:
    Poster Session A: Prostate Cancer

    Type:
    Poster

    Presenting Author:
    Brigida Anna Maiorano

    Poster Board Number:
    D14

    desktop listing bg

    Efficacy and safety of darolutamide monotherapy in patients with castration-sensitive prostate cancer (CSPC) after biochemical recurrence (BCR): 52-week results from ARAMON

    Date/Time:
    February 26, 2026 | 11:30 AM – 12:45 PM; 5:45 PM – 6:45 PM (PST)

    Session:
    Poster Session A: Prostate Cancer

    Type:
    Poster

    Presenting Author:
    Andrew Laccetti

    Poster Board Number:
    E22

    desktop listing bg

    Real-world darolutamide safety and effectiveness in nonmetastatic castration-resistant prostate cancer (nmCRPC) by lipid-modifying agent use: Post hoc analyses of DAROL interim analysis 4 (IA4)

    Date/Time:
    February 26, 2026 | 11:30 AM – 12:45 PM; 5:45 PM – 6:45 PM (PST)

    Session:
    Poster Session A: Prostate Cancer

    Type:
    Poster

    Presenting Author:
    Murilo Luz

    Poster Board Number:
    C6

    desktop listing bg

    Androgen-Receptor pAthwAy inhibitors Triplet therapy (ARAAT): Real-world outcomes in metastatic hormone-sensitive prostate cancer

    Date/Time:
    February 26, 2026 | 11:30 AM – 12:45 PM; 5:45 PM – 6:45 PM (PST)

    Session:
    Poster Session A: Prostate Cancer

    Type:
    Poster

    Presenting Author:
    Alicia K Morgans

    Poster Board Number:
    B15

    desktop listing bg

    Real-world use of novel hormonal therapies in European and North American patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC)

    Date/Time:
    February 26, 2026 | 11:30 AM – 12:45 PM; 5:45 PM – 6:45 PM (PST)

    Session:
    Poster Session A: Prostate Cancer

    Type:
    Poster

    Presenting Author:
    Zdravko Vassilev

    Poster Board Number:
    B19

    desktop listing bg 1070*420

    Impact of hospitalizations on health-related quality of life and overall survival in metastatic castration-sensitive prostate cancer: Insights from the ARANOTE trial

    Date/Time:
    February 27, 2026 | 11:30 AM – 12:45 PM; 5:45 PM – 6:45 PM (PST)

    Session:
    Poster Session B: Prostate Cancer and Urothelial Carcinoma

    Type:
    Poster

    Presenting Author:
    Alicia K Morgans

    Poster Board Number:
    A16

    desktop listing bg 1070*420

    Safety Profile of Darolutamide + ADT compared to Enzalutamide, Apalutamide, and Abiraterone in metastatic castration-sensitive prostate cancer: Results from the First Safety Matching-Adjusted Indirect Comparison

    Date/Time:
    February 26, 2026 | 11:30 AM – 12:45 PM; 5:45 PM – 6:45 PM (PST)

    Session:
    Poster Session A: Prostate Cancer

    Type:
    Poster

    Presenting Author:
    Neal Shore

    Poster Board Number:
    D18

    desktop listing bg 1070*420

    Harnessing caregiver support to improve shared decision-making in metastatic prostate cancer treatment: A US-based quantitative survey

    Date/Time:
    February 26, 2026 | 11:30 AM – 12:45 PM; 5:45 PM – 6:45 PM (PST)

    Session:
    Poster Session A: Prostate Cancer

    Type:
    Poster

    Presenting Author:
    Daniel George

    Poster Board Number:
    D12

    desktop listing bg 1070*420

    Novel androgen receptor inhibitors for the treatment of metastatic castration-sensitive prostate cancer: A cost-effectiveness analysis

    Date/Time:
    February 26, 2026 | 11:30 AM – 12:45 PM; 5:45 PM – 6:45 PM (PST)

    Session:
    Poster Session A: Prostate Cancer

    Type:
    Poster

    Presenting Author:
    William V Padula

    Poster Board Number:
    G5

    desktop listing bg 1070*420

    Discontinuation Rates Among Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) initiating novel androgen receptor inhibitors in Oncology and Non-Oncology settings

    Date/Time:
    February 26, 2026 | 11:30 AM – 12:45 PM; 5:45 PM – 6:45 PM (PST)

    Session:
    Poster Session A: Prostate Cancer

    Type:
    Poster

    Presenting Author:
    Hannus McManus

    Poster Board Number:
    C12

    desktop listing bg 1070*420

    A phase 2 trial of darolutamide to enhance prostate-specific membrane antigen expression in patients with localized prostate cancer (Daro-PET)

    Date/Time:
    February 26, 2026 | 11:30 AM – 12:45 PM; 5:45 PM – 6:45 PM (PST)

    Session:
    Poster Session A: Prostate Cancer

    Type:
    Poster

    Presenting Author:
    Jose Mauricio Mota

    Poster Board Number:
    K2

    desktop listing bg 1070*420

    Impact of age, number of cycles of chemotherapy and presence of visceral metastases on PSA response in patients on triplet therapy (ADT + Darolutamide + Docetaxel) for mHSPC: UK real world data from the RECOMMEND study

    Date/Time:
    February 26, 2026 | 11:30 AM – 12:45 PM; 5:45 PM – 6:45 PM (PST)

    Session:
    Poster Session A: Prostate Cancer

    Type:
    Poster

    Presenting Author:
    Amit Bahl

    Poster Board Number:
    A26

    desktop listing bg 1070*420

    3-Weekly Docetaxel 75 mg/m
    2
    vs 2-Weekly Docetaxel 50 mg/m
    2
    in Combination with Darolutamide + ADT in Patients with mHSPC : Subgroup Analyses from the Randomised Phase 3 ARASAFE Trial

    Date/Time:
    February 26, 2026 | 11:30 AM – 12:45 PM; 5:45 PM – 6:45 PM (PST)

    Session:
    Poster Session A: Prostate Cancer

    Type:
    Poster

    Presenting Author:
    Marc-Oliver Grimm

    Poster Board Number:
    E8

    desktop listing bg 1070*420

    Prognostic significance of depressive symptoms in men with advance prostate cancer (PC): Results from the IRONMAN registry

    Date/Time:
    February 26, 2026 | 11:30 AM – 12:45 PM; 5:45 PM – 6:45 PM (PST)

    Session:
    Poster Session A: Prostate Cancer

    Type:
    Poster

    Presenting Author:
    Elizabeth Tran

    Poster Board Number:
    D20

    desktop listing bg 1070*420

    Sequencing of therapeutic agents before and after metastatic castration-resistant prostate cancer (mCRPC) diagnosis in an international real-world setting

    Date/Time:
    February 26, 2026 | 11:30 AM -12:45 PM; 5:45 PM - 6:45 PM (PST)

    Session:
    Poster Session A: Prostate Cancer

    Type:
    Poster

    Presenting Author:
    Rana R McKay

    Poster Board Number:
    C7

    RADIUM-223

    desktop listing bg 1070*420

    Final Overall Survival Results from the EORTC 1333/PEACE-3 Trial: Enzalutamide With or Without Radium-223 in Metastatic Castration-Resistant Prostate Cancer

    Date/Time:
    February 26, 2026 | 8:15 - 8:25 AM (PST)

    Session:
    Oral Abstract Session A: Prostate Cancer

    Type:
    Oral

    Presenting Author:
    Enrique Gallardo

    Abstract Number:
    15

    desktop listing bg 1070*420

    Long-Term Outcomes With Radium-223 in Metastatic Castration Resistant Prostate Cancer: US Patient Subset of the 10-Year REASSURE Global Study

    Date/Time:
    February 26, 2026 | 11:30 AM – 12:45 PM; 5:45 PM – 6:45 PM (PST)

    Session:
    Poster Session A: Prostate Cancer

    Type:
    Poster

    Presenting Author:
    Celestia Higano

    Poster Board Number:
    B18

    desktop listing bg 1070*420

    Real-world characteristics of long-term survivors with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223): An analysis of the global REASSURE study

    Date/Time:
    February 26, 2026 | 11:30 AM – 12:45 PM; 5:45 PM – 6:45 PM (PST)

    Session:
    Poster Session A: Prostate Cancer

    Type:
    Poster

    Presenting Author:
    Saby George

    Poster Board Number:
    B7

    desktop listing bg 1070*420

    Genomic profiling in circulating tumor DNA from a multicenter prospective study of radium-223 in bone-metastatic castration-resistant prostate cancer: the KYUCOG-1901 study

    Date/Time:
    February 26, 2026 | 11:30 AM – 12:45 PM; 5:45 PM – 6:45 PM (PST)

    Session:
    Poster Session A: Prostate Cancer

    Type:
    Poster

    Presenting Author:
    Masaki Shiota

    Poster Board Number:
    H4

    desktop listing bg 1070*420

    Radium 223 without Androgen Deprivation Therapy (ADT) in Patients (Pts) with Biochemically Recurrent Prostate Cancer (BCR) and PET Findings in the Bones

    Date/Time:
    February 26, 2026 | 11:30 AM – 12:45 PM; 5:45 PM – 6:45 PM (PST)

    Session:
    Poster Session A: Prostate Cancer

    Type:
    Poster

    Presenting Author:
    Melissa L Abel

    Poster Board Number:
    G1

    desktop listing bg 1070*450

    Circulating tumor DNA (ctDNA} dynamics in bone-dominant metastatic castration resistant prostate cancer (mCRPC} treated with radium-223 with or without olaparib: Biomarker analyses from the multicenter, randomized, phase 2, investigator-initiated COMRADE trial

    Date/Time:
    February 26, 2026 | 11:30 AM – 12:45 PM; 5:45 PM – 6:45 PM (PST)

    Session:
    Poster Session A: Prostate Cancer

    Type:
    Poster

    Presenting Author:
    Rana R. McKay

    Poster Board Number:
    E13

    PIPELINE

    desktop listing bg 1070*420

    First-in-human assessment of actinium-225-prostate-specific membrane antigen (
    225
    Ac-PSMA)-Trillium (BAY 3563254) in mCRPC: Dose-escalation results of the Phase 1 PAnTHa study

    Date/Time:
    February 26, 2026 | 5:00 PM PM – 5:45 PM (PST)

    Session:
    Rapid Oral Abstract Session A: Prostate Cancer

    Type:
    Oral

    Presenting Author:
    Fred Saad

    Abstract
    #19

    Footer desktop bg

    Terms and Conditions

    Privacy Policy

    Medical Information

    The compendium provided by Bayer is a compilation of Presentations Sponsored by Bayer & Presentations from Bayer-supported Investigator-Initiated Research. Copies of presentations obtained from this compendium are for personal use only and may not be reproduced or distributed without permission from The American Society of Clinical Oncology (ASCO) and from the authors. The compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities.

    Reused with permission. © 2026 American Society of Clinical Oncology (ASCO). All rights reserved.

    For any questions, please contact Medical Information at 1-888-84-BAYER (1-888-842-2937), or visit go.bayer.com/vPIR

    © 2026 Bayer. All rights reserved. Bayer and the Bayer Cross are registered trademarks of Bayer. 100 Bayer Boulevard, PO Box 915, Whippany, NJ 07981 USA. 2/26

    MA-M_DAR-US-0390-1
    MA-M_DAR-US-0391-1